163 related articles for article (PubMed ID: 34865698)
1. Is there an optimal adjunct therapy to traditional cytotoxic induction?
Michaelis LC
Best Pract Res Clin Haematol; 2021 Dec; 34(4):101326. PubMed ID: 34865698
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials.
Wang H; Xiao X; Xiao Q; Lu Y; Wu Y
Medicine (Baltimore); 2020 Jun; 99(24):e20094. PubMed ID: 32541448
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of 7 cases of pediatric acute myeloid leukemia with DEK-NUP214 fusion gene].
Li XL; Liu LP; Wan Y; Liu F; Chen X; Ren YY; Ruan M; Guo Y; Zhu XF; Yang WY
Zhonghua Er Ke Za Zhi; 2023 Apr; 61(4):357-362. PubMed ID: 37011983
[No Abstract] [Full Text] [Related]
4. Acute myeloid leukemia induction with cladribine: Outcomes by age and leukemia risk.
Schoen MW; Woelich SK; Braun JT; Reddy DV; Fesler MJ; Petruska PJ; Freter CE; Lionberger JM
Leuk Res; 2018 May; 68():72-78. PubMed ID: 29574395
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
[TBL] [Abstract][Full Text] [Related]
6. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
Kim M; Williams S
Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
[TBL] [Abstract][Full Text] [Related]
7. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.
Nazha A; Kantarjian H; Ravandi F; Huang X; Choi S; Garcia-Manero G; Jabbour E; Borthakur G; Kadia T; Konopleva M; Cortes J; Ferrajoli A; Kornblau S; Daver N; Pemmaraju N; Andreeff M; Estrov Z; Du M; Brandt M; Faderl S
Am J Hematol; 2013 Nov; 88(11):961-6. PubMed ID: 23877926
[TBL] [Abstract][Full Text] [Related]
8. [Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
Qin T; Xu Z; Zhang Y; Lin Y; Ru K; Fang L; Zhang H; Pan L; Hu N; Qu S; Wang J; Xing R; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):94-9. PubMed ID: 27014976
[TBL] [Abstract][Full Text] [Related]
9. Comparison of anthracyclines used for induction chemotherapy in patients with FLT3-ITD-mutated acute myeloid leukemia.
Choi EJ; Lee JH; Lee JH; Park HS; Ko SH; Hur EH; Moon J; Goo BK; Kim Y; Seol M; Lee YS; Kang YA; Jeon M; Woo JM; Lee KH
Leuk Res; 2018 May; 68():51-56. PubMed ID: 29544132
[TBL] [Abstract][Full Text] [Related]
10. How can one optimize induction therapy in AML?
Luger SM
Best Pract Res Clin Haematol; 2017 Dec; 30(4):301-305. PubMed ID: 29156199
[TBL] [Abstract][Full Text] [Related]
11. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study.
Ohtake S; Miyawaki S; Fujita H; Kiyoi H; Shinagawa K; Usui N; Okumura H; Miyamura K; Nakaseko C; Miyazaki Y; Fujieda A; Nagai T; Yamane T; Taniwaki M; Takahashi M; Yagasaki F; Kimura Y; Asou N; Sakamaki H; Handa H; Honda S; Ohnishi K; Naoe T; Ohno R
Blood; 2011 Feb; 117(8):2358-65. PubMed ID: 20693429
[TBL] [Abstract][Full Text] [Related]
12. Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience.
Tefferi A; Gangat N; Shah M; Alkhateeb H; Patnaik MS; Al-Kali A; Elliott MA; Hogan WJ; Litzow MR; Hook CC; Mangaonkar A; Viswanatha D; Chen D; Pardanani A; Ketterling RP; Begna KH
Haematologica; 2022 Oct; 107(10):2474-2479. PubMed ID: 35734931
[No Abstract] [Full Text] [Related]
13. [Comparison of the efficacy of IA and HAD induction regimens in the treatment of patients with newly diagnosed acute myeloid leukemia: a single-center study].
Zhang CX; Qiu SW; Gong BF; Gong XY; Li Y; Liu YT; Fang QY; Zhang GJ; Liu KQ; Zhou CL; Wei SN; Lin D; Liu BC; Wang Y; Mi YC; Wei H; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):383-387. PubMed ID: 35680595
[No Abstract] [Full Text] [Related]
14. Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine.
Wiedower E; Jamy O; Martin MG
Anticancer Res; 2015 Nov; 35(11):6287-90. PubMed ID: 26504064
[TBL] [Abstract][Full Text] [Related]
15. Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
Borlenghi E; Cattaneo C; Cerqui E; Archetti S; Bertoli D; Bellotti D; Gramegna D; Soverini G; Oberti M; Schieppati F; Pagani C; Passi A; Sciumé M; Farina M; Carbone C; Crippa C; Dalceggio D; Tucci A; Rossi G
Hematol Oncol; 2020 Dec; 38(5):754-762. PubMed ID: 32950042
[TBL] [Abstract][Full Text] [Related]
16. Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives.
Guolo F; Minetto P; Clavio M; Miglino M; Lemoli RM; Gobbi M
Biosci Trends; 2017 Mar; 11(1):110-114. PubMed ID: 28123146
[TBL] [Abstract][Full Text] [Related]
17. Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results.
Pigneux A; Perreau V; Jourdan E; Vey N; Dastugue N; Huguet F; Sotto JJ; Salmi LR; Ifrah N; Reiffers J
Haematologica; 2007 Oct; 92(10):1327-34. PubMed ID: 18024370
[TBL] [Abstract][Full Text] [Related]
18. Cytarabine and daunorubicin for the treatment of acute myeloid leukemia.
Murphy T; Yee KWL
Expert Opin Pharmacother; 2017 Nov; 18(16):1765-1780. PubMed ID: 29017371
[TBL] [Abstract][Full Text] [Related]
19. Comparison of efficacy between homoharringtonine, aclarubicin, cytarabine (HAA) and idarubicin, cytarabine (IA) regimens as induction therapy in patients with de novo core binding factor acute myeloid leukemia.
Duan W; Yang S; Zhao T; Hu L; Qin Y; Jia J; Wang J; Lu S; Jiang H; Zhang X; Xu L; Wang Y; Lai Y; Shi H; Huang X; Jiang Q
Ann Hematol; 2023 Oct; 102(10):2695-2705. PubMed ID: 37572135
[TBL] [Abstract][Full Text] [Related]
20. Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial.
Pluta A; Robak T; Wrzesien-Kus A; Katarzyna Budziszewska B; Sulek K; Wawrzyniak E; Czemerska M; Zwolinska M; Golos A; Holowiecka-Goral A; Kyrcz-Krzemien S; Piszcz J; Kloczko J; Mordak-Domagala M; Lange A; Razny M; Madry K; Wiktor-Jedrzejczak W; Grosicki S; Butrym A; Kuliczkowski K; Warzocha K; Holowiecki J; Giebel S; Szydlo R; Wierzbowska A
Am J Hematol; 2017 Apr; 92(4):359-366. PubMed ID: 28103640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
